Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

Purple Biotech Highlights Significant Advantages

of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

REHOVOT, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple

Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek

to overcome tumor immune evasion and drug resistance, today announced the presentation of new preclinical data on its novel CAPTN-3 tri-specific

antibody platform in a poster presentation at the 2025 Annual Congress of the European Association for Cancer Research (EACR 2025), that was

held in Lisbon, Portugal from June 16-19, 2025.

"Purple's proprietary CAPTN-3 platform of T-cell

engagers enables the creation of a large number of antibodies to different targets, and by capping the anti-CD3 arm for conditional

activation and adding an NK cell antibody arm, we are creating tri-specific antibodies that safely activate both the innate and adaptive

immune systems," said Gil Efron, Purple Biotech CEO. "Our poster at EACR 2025 highlights the flexibility and efficiency of

The design of the CAPTN-3 lead product and other candidates in this

platform includes an anti-NKG2A arm, which acts both as an NK cell antigen and as an immune checkpoint on both T cells and NK cells through

its interaction with HLA-E, which is often upregulated in tumors to evade immune detection.

NKG2A expression identifies a subset of human gamma delta 2 T cells exerting the highest antitumor effector functions. Anti-NKG2A function

is required to unleash the NKG2A+ gamma delta 2 T cell anti-cancer activity. Our data demonstrate that the NKG2A arm in CAPTN-3 TCE synergizes

with the anti-CD3 arm to induce significant cytotoxic effects against solid tumor cells.

NKG2A is an immune checkpoint that plays an important role in the exhaustion

of cytotoxic T cells in the tumor microenvironment (TME). The preclinical data demonstrate the potential of CAPTN-3 to re-invigorate

exhausted T cells and efficiently kill solid tumor cells, largely attributed to the significant contribution of the unique anti-NKG2A

These activities are further supported by the in-vivo data demonstrating

that both the NKG2A and CD3 arms contribute to the sustained tumor regression observed in mice models. These results underscore the innovative

design of CAPTN-3, highlighting the impact of the novel anti-NKG2A arm and its synergistic effect with the anti-CD3 arm.

The CAPTN-3 platform creates a tri-specific scaffold with three binding

arms. In the variable region, one arm conditionally binds to CD3, only after the cap has been cleaved by proteases in the TME. The other

variable region engages natural killer (NK) cells, activating the innate immune system to join activated T cells in the killing of tumor

cells. The constant region of the tri-specific antibody targets tumor associated antigens (TAA) to recruit both NK and T cells to the

tumor. Through activation of both the innate and adaptive immune systems, the CAPTN-3 platform can generate synergistic responses within

the TME, without the risk of off-target cytokine release.

Key Highlights from the Poster Presentation:

EACR 2025 poster details are as follows:

Abstract #: EACR25-1964

Title: "CAPTN-3: A novel platform of conditionally activated

T cell and NK cell engagers"

Session Title: Immunotherapy

The poster is available in the Publications section on Purple

Abstracts related to the EACR meeting will be published online

following the presentation. For more information, please visit the EACR 2025 website.

About Purple Biotech

Purple Biotech Ltd. (NASDAQ/TASE: PPBT)

is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The Company's

oncology pipeline includes CM24, NT219, and CAPTN-3. CM24 is a humanized monoclonal antibody that blocks CEACAM1, which supports tumor

immune evasion and survival through multiple pathways. CEACAM1 on tumor cells, immune cells and neutrophil extracellular traps is a novel

target for the treatment of multiple cancer indications. As proof of concept of these novel pathways, the Company completed a Phase 2

study for the treatment of pancreatic ductal adenocarcinoma (PDAC) with CM24 as a combination therapy with the anti-PD-1 checkpoint inhibitor

nivolumab and chemotherapy, demonstrating clear and consistent improvement across all efficacy endpoints and the identification of two

potential serum biomarkers. NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. A Phase 1 dose

escalation study was concluded as a monotherapy and in combination with cetuximab, in which NT219 demonstrated anti-tumor activity in

combination with cetuximab in second-line patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M

SCCHN). A Phase 2 study, in collaboration with the University of Colorado, to treat R/M SCCHN patients with NT219 in combination with

cetuximab or pembrolizumab. was initiated. The Company is also advancing CAPTN-3, a preclinical platform of conditionally activated tri-specific

antibodies, which engage both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. The

cleavable capping technology confines the compound's therapeutic activity to the local tumor microenvironment, thereby potentially increasing

the anticipated therapeutic window in patients. The third arm specifically targets the Tumor Associated Antigen (TAA). The technology

presents a novel mechanism of action by unleashing both innate and adaptive immune systems to induce an optimal anti-tumoral immune response.

IM1240 is the first tri-specific antibody in development that targets the 5T4 antigen, which is expressed in a variety of solid tumors

and is associated with advanced disease, increased invasiveness, and poor clinical outcomes. The Company's corporate headquarters are

located in Rehovot, Israel. For more information, please visit https://purple-biotech.com/.

Forward-Looking Statements and Safe Harbor Statement

Certain statements in this press release that are forward-looking and

not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities

Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements that are not statements of

historical fact, and may be identified by words such as "believe", "expect", "intend", "plan",

"may", "should", "could", "might", "seek", "target", "will", "project",

"forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable

words or by the fact that these statements do not relate strictly to historical matters. You should not place undue reliance on these

forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect our current views, expectations,

beliefs or intentions with respect to future events, and are subject to a number of assumptions, involve known and unknown risks, many

of which are beyond our control, as well as uncertainties and other factors that may cause our actual results, performance or achievements

to be significantly different from any future results, performance or achievements expressed or implied by the forward-looking statements.

Important factors that could cause or contribute to such differences include, among others, risks relating to: the plans, strategies and

objectives of management for future operations; product development for NT219, CM24 and IM1240; the process by which such early stage

therapeutic candidates could potentially lead to an approved drug product is long and subject to highly significant risks, particularly

with respect to a joint development collaboration; the fact that drug development and commercialization involves a lengthy and expensive

process with uncertain outcomes; our ability to successfully develop and commercialize our pharmaceutical products; the expense, length,

progress and results of any clinical trials; the impact of any changes in regulation and legislation that could affect the pharmaceutical

industry; the difficulty in receiving the regulatory approvals necessary in order to commercialize our products; the difficulty of predicting

actions of the U.S. Food and Drug Administration or any other applicable regulator of pharmaceutical products; the regulatory environment

and changes in the health policies and regimes in the countries in which we operate; the uncertainty surrounding the actual market reception

to our pharmaceutical products once cleared for marketing in a particular market; the introduction of competing products; patents obtained

by competitors; dependence on the effectiveness of our patents and other protections for innovative products; our ability to obtain, maintain

and defend issued patents; the commencement of any patent interference or infringement action against our patents, and our ability to

prevail, obtain a favorable decision or recover damages in any such action; and the exposure to litigation, including patent litigation,

and/or regulatory actions, and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2024

and in our other filings with the U.S. Securities and Exchange Commission ("SEC"), including our cautionary discussion of risks

and uncertainties under "Risk Factors" in our Registration Statements and Annual Reports. These are factors that we believe

could cause our actual results to differ materially from expected results. Other factors besides those we have listed could also adversely

affect us. Any forward-looking statement in this press release speaks only as of the date which it is made. We disclaim any intention

or obligation to publicly update or revise any forward-looking statement or other information contained herein, whether as a result of

new information, future events or otherwise, except as required by applicable law. You are advised, however, to consult any additional

disclosures we make in our reports to the SEC, which are available on the SEC's website, https://www.sec.gov.